Aimmune Therapeutics (AIMT) Lowered to “Sell” at Zacks Investment Research

Zacks Investment Research downgraded shares of Aimmune Therapeutics (NASDAQ:AIMT) from a hold rating to a sell rating in a research report sent to investors on Monday.

According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “

Several other analysts have also issued reports on AIMT. Piper Jaffray Companies set a $38.00 price target on shares of Aimmune Therapeutics and gave the company a buy rating in a research report on Saturday, October 21st. Wedbush restated an outperform rating and set a $70.00 price target (up from $42.00) on shares of Aimmune Therapeutics in a research report on Monday, October 23rd. Credit Suisse Group upped their price target on shares of Aimmune Therapeutics from $36.00 to $45.00 and gave the company an outperform rating in a research report on Monday, October 23rd. Roth Capital started coverage on shares of Aimmune Therapeutics in a research report on Monday, November 20th. They set a buy rating and a $60.00 price target for the company. Finally, ValuEngine lowered shares of Aimmune Therapeutics from a hold rating to a sell rating in a research report on Friday, December 1st. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $55.43.

Aimmune Therapeutics (NASDAQ:AIMT) traded down $0.35 on Monday, reaching $38.65. The company had a trading volume of 357,000 shares, compared to its average volume of 394,862. The company has a market capitalization of $2,010.00 and a PE ratio of -16.52. Aimmune Therapeutics has a 1-year low of $15.97 and a 1-year high of $40.00.

Aimmune Therapeutics (NASDAQ:AIMT) last released its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.09. research analysts predict that Aimmune Therapeutics will post -2.51 EPS for the current fiscal year.

In other news, CEO Stephen George Dilly sold 1,154 shares of the stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $26.24, for a total transaction of $30,280.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Susan E. Barrowcliffe sold 75,000 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $37.14, for a total transaction of $2,785,500.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 137,946 shares of company stock valued at $4,991,189. Company insiders own 17.59% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC boosted its holdings in shares of Aimmune Therapeutics by 10.1% during the second quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 499 shares during the period. Daiwa SB Investments Ltd. boosted its holdings in shares of Aimmune Therapeutics by 44.5% during the fourth quarter. Daiwa SB Investments Ltd. now owns 7,290 shares of the biotechnology company’s stock worth $276,000 after purchasing an additional 2,245 shares during the period. Legal & General Group Plc boosted its holdings in shares of Aimmune Therapeutics by 26.6% during the second quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock worth $160,000 after purchasing an additional 1,634 shares during the period. Voya Investment Management LLC boosted its holdings in shares of Aimmune Therapeutics by 31.2% during the second quarter. Voya Investment Management LLC now owns 15,781 shares of the biotechnology company’s stock worth $324,000 after purchasing an additional 3,757 shares during the period. Finally, Franklin Street Advisors Inc. NC boosted its holdings in shares of Aimmune Therapeutics by 43.8% during the fourth quarter. Franklin Street Advisors Inc. NC now owns 16,420 shares of the biotechnology company’s stock worth $621,000 after purchasing an additional 5,000 shares during the period. Institutional investors own 73.34% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Aimmune Therapeutics (AIMT) Lowered to “Sell” at Zacks Investment Research” was originally posted by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://weekherald.com/2018/01/12/aimmune-therapeutics-aimt-lowered-to-sell-at-zacks-investment-research.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get a free copy of the Zacks research report on Aimmune Therapeutics (AIMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply